Evidence map›Paper›PMID 38902577›Full record

ArticleTherapeutic innovation & regulatory science2024

Harmonizing Quality Improvement Metrics Across Global Trial Networks to Advance Paediatric Clinical Trials Delivery.

Sabah Attar, Angie Price, Collin Hovinga, Breanne Stewart, Thierry Lacaze-Masmonteil, Fedele Bonifazi, Mark A Turner, Ricardo M Fernandes

Abstract read
In one paragraph

Article in Therapeutic innovation & regulatory science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Identifying and Deploying Benchmarks for Clinical Research at Sites.Therapeutic innovation & regulatory science · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sabah AttarDepartment of Women's and Children's Health, Liverpool Women's NHS Foundation Trust, University of Liverpool, Crown Street, Liverpool, L8 7SS, UK. sgattar@liverpool.ac.uk.
Angie PriceSite Network - Quality Improvement, Institute for Advanced Clinical Trials for Children, 9200 Corporate Blvd, Suite 350, Rockville, MD, 20850, USA.
Collin HovingaClinical and Scientific Development, Institute for Advanced Clinical Trials for Children, 9200 Corporate Blvd, Suite 350, Rockville, MD, 20850, USA.
Breanne StewartClinical Trials Office, College of Health Sciences, Faculty of Medicine and Dentistry, University of Alberta, 400 College Plaza 8215 - 112 Street, Edmonton, AB, T6G 2C8, Canada.
Thierry Lacaze-MasmonteilMaternal Infant Child Youth Research Network, Vancouver, BC, Canada.
Fedele BonifaziFondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Via Abate Eustasio, 30, 70010, Valenzano, BA, Italy.
Mark A Turnerconect4children Stichting, Utrecht, The Netherlands.
Ricardo M Fernandesconect4children Stichting, Utrecht, The Netherlands.

Funding

Innovative Medicines Initiative 777389
6 · The paper itself

Abstract

backgroundDespite global efforts to improve paediatric clinical trials, significant delays continue in paediatric drug approvals. Collaboration between research networks is needed to address these delays. This paper is a first step to promote interoperability between paediatric networks from different jurisdictions by comparing drivers for, and content of, metrics about clinical trial conduct.

methodsThree paediatric networks, Institute for Advanced Clinical Trials for Children, the Maternal Infant Child and Youth Research Network and conect4children, have each developed metrics to address delays and create efficiencies. We identified the methodology by which each network identified metrics, described the metrics of each network, and mapped consistency to come to consensus about core metrics that networks could share.

resultsMetric selection was driven by site quality improvement in one network (11 metrics), by network performance in one network (13 metrics), and by both in one network (five metrics). The domains of metrics were research capacity/capability, site identification/feasibility, trial start-up, and recruitment/enrolment. The network driven by site quality improvement did not have indicators for capacity/capability or identification/feasibility. Fifteen metrics for trial start up and conduct were identified. Metrics related to site approvals were found in all three networks. The themes for metrics can inform the development of 'shared' metrics.

conclusionWe found disparity in drivers, methodology and metrics. Tackling this disparity will result in a unified approach to addressing delays in paediatric drug approvals. Collaborative work to define inter-operable metrics globally is outlined.

Indexed as

Clinical Trials as TopicPediatricsQuality ImprovementChildDrug ApprovalHumansClinical trialsMetricsNetworksPaediatricsPerformanceQuality

Identifiers

PMID38902577
PMCPMC11335960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.